Fiche centre
Centrum Medyczne Plejady
Krakow — Poland
Essais liés16clinical trials
VilleKrakowlocalisation
PaysPolandlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06798896
Essais cliniques associés
16| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Carisbamate | Épilepsie | Phase 3 | NCT05219617 | Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults | RECRUITING |
| SPN-817 | Épilepsie | Phase 2 | NCT06798896 | RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures | RECRUITING |
| TAK-935 | Épilepsie | Phase 2 | NCT03650452 | ELEKTRA — A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies | COMPLETED |
| Soticlestat | Épilepsie | Phase 3 | NCT04940624 | A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome | COMPLETED |
| Soticlestat | Épilepsie | Phase 2 | NCT03635073 | Endymion 1 — A Study of Soticlestat in Adults and Children With Rare Epilepsies | TERMINATED |
| Soticlestat | Épilepsie | Phase 3 | NCT05163314 | A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome | TERMINATED |
| Soticlestat | Épilepsie | Phase 3 | NCT04938427 | A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome | COMPLETED |
| M5049 low dose | Lupus | Phase 2 | NCT05540327 | The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE) | ACTIVE_NOT_RECRUITING |
| Cenerimod | Lupus | Phase 3 | NCT05648500 | OPUS-1 — A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus | ACTIVE_NOT_RECRUITING |
| Cenerimod 0.5 mg | Lupus | Phase 2 | NCT03742037 | Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus | COMPLETED |
| Eptinezumab | Migraine | Phase 3 | NCT05897320 | PROSPECT-1 — A Study of Eptinezumab in Pediatric Participants With Episodic Migraine | RECRUITING |
| Eptinezumab | Migraine | Phase 3 | NCT05164172 | REJOIN — A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine | RECRUITING |
| Eptinezumab | Migraine | Phase 3 | NCT04965675 | PROSPECT-2 — A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine | RECRUITING |
| Rimegepant (PF-07899801) | Migraine | Phase 3 | NCT04743141 | Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine | RECRUITING |
| Xcopri | Épilepsie | Phase 3 | NCT05067634 | Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures | COMPLETED |
| Rimegepant/BHV3000 | Migraine | Phase 3 | NCT04649242 | Randomized Study in Children and Adolescents With Migraine: Acute Treatment | RECRUITING |